Sector consensus Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.89 USD | -1.95% |
|
+13.17% | +17.80% |
| 08-10 | Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date | MT |
| 08-10 | Novo Nordisk works to address FDA's findings at Indiana plant | FW |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 59.94 | +15.51% | 16 | ||||||
| 176.94 | +9.67% | 18 | ||||||
| 1,037.68 | +17.12% | 15 | ||||||
| 200.05 | +48.46% | 22 | ||||||
| 40.47 | +2.01% | 22 | ||||||
| 104.26 | +29.88% | 20 | ||||||
| 2,403.92 | +20.68% | 15 | ||||||
| 1,073.31 | -19.3% | 7 | ||||||
| 567.11 | +7.31% | 17 | ||||||
| 52.94 | -0.04% | 16 | ||||||
| 110.18 | +24.74% | 11 | ||||||
| 145.4 | +66.47% | 20 | ||||||
| 678.06 | +31.58% | 16 | ||||||
| 21.06 | +91.49% | 13 | ||||||
| 108.85 | +40.47% | 20 | ||||||
| 100.13 | +37.35% | 15 | ||||||
| 121.5 | +15.35% | 14 | ||||||
| 85.5 | +1.6% | 10 | ||||||
| 109 | +87% | 9 | ||||||
| 12.75 | +70.23% | 4 | ||||||
| Average | 360.45 | +29.88% | 15 | ||||||
| Weighted average by Cap. | 446.6 | +23.56% | 16 |
- Stock Market
- Stocks
- SRRK Stock
- Sector Scholar Rock Holding Corporation
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
